PURPOSE: HIV protease inhibitors are associated with HIV protease inhibitor-related lipodystrophy syndrome. We hypothesized that liposarcomas would be similarly susceptible to the apoptotic effects of an HIV protease inhibitor, nelfinavir. METHODS: We conducted a phase I trial of nelfinavir for liposarcomas. There was no limit to prior chemotherapy. The starting dose was 1,250 mg twice daily (Level 1). Doses were escalated in cohorts of three to a maximally evaluated dose of 4,250 mg (Level 5). One cycle was 28 days. Steady-state pharmacokinetics (PKs) for nelfinavir and its primary active metabolite, M8, were determined at Levels 4 (3,000 mg) and 5. RESULTS: Twenty subjects (13 males) were enrolled. Median (range) age was 64 years (37-81). One subject at Level 1 experienced reversible, grade 3 pancreatitis after 1 week and was replaced. No other dose-limiting toxicities were observed. Median (range) number of cycles was 3 (0.6-13.5). Overall best responses observed were 1 partial response, 1 minor response, 4 stable disease, and 13 progressive disease. Mean peak plasma levels and AUCs for nelfinavir were higher at Level 4 (7.3 mg/L; 60.9 mg/L × h) than 5 (6.3 mg/L; 37.7 mg/L × h). The mean ratio of M8:nelfinavir AUCs for both levels was ~1:3. CONCLUSIONS: PKs demonstrate auto-induction of nelfinavir clearance at the doses studied, although the mechanism remains unclear. Peak plasma concentrations were within range where anticancer activity was demonstrated in vitro. M8 metabolite is present at ~1/3 the level of nelfinavir and may also contribute to the anticancer activity observed.
PURPOSE: HIV protease inhibitors are associated with HIV protease inhibitor-related lipodystrophy syndrome. We hypothesized that liposarcomas would be similarly susceptible to the apoptotic effects of an HIV protease inhibitor, nelfinavir. METHODS: We conducted a phase I trial of nelfinavir for liposarcomas. There was no limit to prior chemotherapy. The starting dose was 1,250 mg twice daily (Level 1). Doses were escalated in cohorts of three to a maximally evaluated dose of 4,250 mg (Level 5). One cycle was 28 days. Steady-state pharmacokinetics (PKs) for nelfinavir and its primary active metabolite, M8, were determined at Levels 4 (3,000 mg) and 5. RESULTS: Twenty subjects (13 males) were enrolled. Median (range) age was 64 years (37-81). One subject at Level 1 experienced reversible, grade 3 pancreatitis after 1 week and was replaced. No other dose-limiting toxicities were observed. Median (range) number of cycles was 3 (0.6-13.5). Overall best responses observed were 1 partial response, 1 minor response, 4 stable disease, and 13 progressive disease. Mean peak plasma levels and AUCs for nelfinavir were higher at Level 4 (7.3 mg/L; 60.9 mg/L × h) than 5 (6.3 mg/L; 37.7 mg/L × h). The mean ratio of M8:nelfinavir AUCs for both levels was ~1:3. CONCLUSIONS: PKs demonstrate auto-induction of nelfinavir clearance at the doses studied, although the mechanism remains unclear. Peak plasma concentrations were within range where anticancer activity was demonstrated in vitro. M8 metabolite is present at ~1/3 the level of nelfinavir and may also contribute to the anticancer activity observed.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Gabriel O de la Garza; Ameera F Ismail; Carryn M Anderson; Werner W Wilke; Mohammed M Milhem; Henry T Hoffman; John M Buatti Journal: Pract Radiat Oncol Date: 2011-10-26
Authors: Peter Pyrko; Adel Kardosh; Weijun Wang; Wenyong Xiong; Axel H Schönthal; Thomas C Chen Journal: Cancer Res Date: 2007-11-15 Impact factor: 12.701
Authors: Susan L Ettinger; Richard Sobel; Tanis G Whitmore; Majid Akbari; Dawn R Bradley; Martin E Gleave; Colleen C Nelson Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Zibin Jiang; Nabendu Pore; George J Cerniglia; Rosemarie Mick; Maria-Magdelena Georgescu; Eric J Bernhard; Stephen M Hahn; Anjali K Gupta; Amit Maity Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: David C Boettiger; Caroline A Sabin; Andrew Grulich; Lene Ryom; Fabrice Bonnet; Peter Reiss; Antonella d'arminio Monforte; Ole Kirk; Andrew Phillips; Mark Bower; Gerd Fätkenheuer; Jens D Lundgren; Matthew Law Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Christoph Driessen; Marianne Kraus; Markus Joerger; Hilde Rosing; Jürgen Bader; Felicitas Hitz; Catherine Berset; Alexandros Xyrafas; Hanne Hawle; Gregoire Berthod; Hermann S Overkleeft; Christiana Sessa; Alwin Huitema; Thomas Pabst; Roger von Moos; Dagmar Hess; Ulrich J M Mey Journal: Haematologica Date: 2015-12-11 Impact factor: 9.941
Authors: Nene N Kalu; Prashant J Desai; Courtney M Shirley; Wade Gibson; Phillip A Dennis; Richard F Ambinder Journal: J Virol Date: 2014-02-26 Impact factor: 5.103
Authors: Gideon M Blumenthal; Joell J Gills; Marc S Ballas; Wendy B Bernstein; Takefumi Komiya; Roopa Dechowdhury; Betsy Morrow; Hyejeong Root; Guinevere Chun; Cynthia Helsabeck; Seth M Steinberg; Jaclyn LoPiccolo; Shigeru Kawabata; Erin R Gardner; William D Figg; Phillip A Dennis Journal: Oncotarget Date: 2014-09-30
Authors: Charlotte E Johnson; David K Hunt; Marie Wiltshire; Terry P Herbert; Julian R Sampson; Rachel J Errington; D Mark Davies; Andrew R Tee Journal: Mol Oncol Date: 2014-11-22 Impact factor: 6.603
Authors: William W Tseng; Neeta Somaiah; Alexander J Lazar; Dina C Lev; Raphael E Pollock Journal: Cancers (Basel) Date: 2013-05-10 Impact factor: 6.639